Cannabinoid

Premium Jane One of First USA Companies to Offer THCA Hemp Flower Online

Retrieved on: 
Wednesday, November 15, 2023
Magic, Cannabinoid, Premium, Safety, THCA, THC, Research, Name, Trust, Life insurance, Online shopping, Hemp, CBD

"Premium Jane has been one of the most trusted names in the CBD industry for years," says Premium Jane owner Jeff Yauck.

Key Points: 
  • "Premium Jane has been one of the most trusted names in the CBD industry for years," says Premium Jane owner Jeff Yauck.
  • "With this new THCA hemp-derived flower line, we are taking a bold step into exciting new territory, providing consumers with a unique way to experience the magic of Hemp."
  • The new Premium Jane THCA hemp-derived flower line is grown in the USA and lab-tested to ensure purity and verify levels of THCA and other cannabinoids.
  • "Premium Jane THCA flower is a result of meticulous cultivation and years of dedication to delivering the most exciting and powerful products on the market."

Wyld Introduces New Boysenberry Sleep Gummies

Retrieved on: 
Tuesday, November 14, 2023
Sleep, CBN, Cannabinol, Terpene, Cannabinoid, Cannabis, Climate, THC, Pomegranate, Marketing, Cannabidiol, CBD

CLACKAMAS, Ore., Nov. 14, 2023 /PRNewswire/ -- Wyld, one of the top five cannabis brands in the U.S., known for their best-selling cannabis infused edibles, is introducing a new sleep gummy, Boysenberry 1:1:1 THC:CBD:CBN Indica-enhanced, across the country.

Key Points: 
  • CLACKAMAS, Ore., Nov. 14, 2023 /PRNewswire/ -- Wyld, one of the top five cannabis brands in the U.S., known for their best-selling cannabis infused edibles, is introducing a new sleep gummy, Boysenberry 1:1:1 THC:CBD:CBN Indica-enhanced, across the country.
  • The boysenberry gummy is Wyld's first to include three cannabinoids – THC, CBD (cannabidiol), and CBN (cannabinol) – as well as botanical terpenes.
  • This addition to Wyld's sleep collection joins their Elderberry 2:1 THC:CBN gummy, which is the bestselling cannabis edible in the country according to BDSA data.
  • Wyld's Boysenberry Indica-enhanced gummies is available in the U.S.

Cronos Group Reports 2023 Third Quarter Results

Retrieved on: 
Wednesday, November 8, 2023
Shekel, Gems, Cannabis, Sale, Vii, Biomass, Flower, Fleming Companies, Inc, Tax, Pressure, Genetics, Grow Up, Wind, CBN, Research, GMO, CBG, Edible, Q3, Growth, Spinach, Marketing, Lord, Pharmacy, Capital expenditure, CBC, Depreciation, Cannabinol, Cannabinoid, Investment, THCV, Capital, Peace, Bookkeeping, Drug, Pharmaceutical industry, Security (finance), Cronos

Furthermore, the weakened Canadian dollar and New Israeli Shekel against the U.S. dollar during the period adversely impacted results.

Key Points: 
  • Furthermore, the weakened Canadian dollar and New Israeli Shekel against the U.S. dollar during the period adversely impacted results.
  • Cronos GrowCo reported to the Company preliminary unaudited net revenue to licensed producers, excluding sales to the Company, of approximately $6.2 million in the third quarter of 2023.
  • In addition to principal repayment, Cronos also received $1.2 million in interest payments from GrowCo, totaling approximately $2.3 million in cash payments to Cronos in Q3 2023.
  • ET to discuss 2023 Third Quarter business results.

PAX Debuts Novel, Science-Backed Product for Better Sleep

Retrieved on: 
Tuesday, November 7, 2023
Women, Cannabis, Men, Specialty, Alternative Medicine, General Health, Consumer, Health, Retail, Natural Resources, High Times, FDA, Pax Labs, Obesity, TIME, PAX, Terpene, Diabetes, Doctor of Philosophy, CBN, Research, ERA, Dementia, Multimedia, National Health, All rights reserved, Disease, Medicine, Risk, Somnolence, GQ, Cannabinol, Accident, Culture, Depression, Cannabinoid, Anxiety, National Health Interview Survey, Insomnia, Diagnosis, Obstructive sleep apnea, Pharmaceutical industry, Video game, Sleep

PAX , a leading global cannabis brand, today announced the launch of Sleep by PAX, a first-of-its-kind, science-driven inhalable pod formula for the PAX Era platform.

Key Points: 
  • PAX , a leading global cannabis brand, today announced the launch of Sleep by PAX, a first-of-its-kind, science-driven inhalable pod formula for the PAX Era platform.
  • Sleep by PAX leverages a unique blend of cannabinoids and terpenes, developed to help consumers get to sleep faster, improve their sleep quality and ultimately get more restorative sleep.
  • Many Americans are sleep-deprived, which is having a significant impact on health and wellbeing,” said Brian Witlin, VP of Product Development at PAX.
  • Sleep by PAX is now available in a 1G pod format in Colorado starting at $40 and in Massachusetts starting at $60.

EQS-News: Cannovum Cannabis AG: Legalization of cannabis is imminent, new premium partners enrich Anbau-Allianz, Cannovum's cultivation alliance

Retrieved on: 
Tuesday, November 7, 2023
Cannabis, Health, ISIN, Partner (business rank), Bundestag, MBDA Deutschland GmbH, Safety, Cannabinoid, AI, Automation, Drug

Cannovum Cannabis AG: Legalization of cannabis is imminent, new premium partners enrich Anbau-Allianz, Cannovum's cultivation alliance

Key Points: 
  • Cannovum Cannabis AG: Legalization of cannabis is imminent, new premium partners enrich Anbau-Allianz, Cannovum's cultivation alliance
    The issuer is solely responsible for the content of this announcement.
  • Cannovum Cannabis AG: Legalization of cannabis is imminent, new premium partners enrich Anbau-Allianz, Cannovum's cultivation alliance
    The legalization of cannabis for recreational use in Germany is imminent.
  • WESSLING will play an important role in quality assurance in the course of the legalization of recreational cannabis in the cultivation alliance for Germany.
  • "We strive for the highest quality and safety in cannabis cultivation," says Tim Spieker, Managing Director of the Cultivation Alliance for Germany.

Cronos Unveils its New THCV Products: Spinach FEELZ™ Full Tilt

Retrieved on: 
Monday, October 30, 2023
THC, CBD, Head, Full Tilt, Cannabinoid, Spinach, THCV, TSX

TORONTO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabinoid company, announced the launch of two new THCV-infused products; Spinach FEELZ™ Full Tilt THCV vape and gummy.

Key Points: 
  • TORONTO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabinoid company, announced the launch of two new THCV-infused products; Spinach FEELZ™ Full Tilt THCV vape and gummy.
  • Cronos also plans to launch a THCV-infused pre-roll under the Spinach FEELZ™ brand, which will add an additional offering under its robust and growing pre-roll portfolio.
  • The Full Tilt THCV lineup is designed to give adult consumers an exciting new cannabis experience.
  • “We’re incredibly excited about the possibilities of THCV and these new products under the Spinach FEELZ™ Full Tilt lineup do not disappoint,” said Mike Gorenstein, Chairman, President, and CEO, Cronos.

CORRECTION/RETRACTION: New to The Street Announces Four Corporate Interviews on its 525th Show, Airing on the Fox Business Network, Monday, October 30, 2023, at 10:30 PM PT

Retrieved on: 
Friday, October 27, 2023
Ethos, Dark, Rat, American College, Social media, FRA, Pressure, Genetics, Elective surgery, Interview, Third party, Disease, Hacking, Record, Cannabinoid, IP, Pain, Birthday, Sale, Veterinarian, Cat, ACVS, American College of Veterinary Surgeons, Injury, Internet, Osteoarthritis, Dog, Innovation system, Web page, 23andMe, Horse, FMW, BEC, Food, Coffee, Medical cannabis, Conference, Cosmetics, CSE, Quality of life, Animal, Privacy, Epilepsy, Communication, Email spoofing, FDA, Water, Patent, OTCQX, Absorption, PROMO, Electricity, OTCQB, Television, Cryptocurrency, CBD, Street

New to The Street’s 525th TV episode features the following four (4) Companies and their representatives:

Key Points: 
  • New to The Street’s 525th TV episode features the following four (4) Companies and their representatives:
    1).
  • The study demonstrated the efficacy of Spryng as an excellent, non-invasive alternative in treating dogs with cranial cruciate disease and injuries.
  • John believes as more published studies prove the viability of Spryng more veterinarians will adopt it as a front-line treatment.
  • PETV's Spryng is becoming more widely known as an effective disruptive technology for treating dogs, horses, and cats with osteoarthritis.

New to The Street Announces Five Corporate Interviews on its 525th Show, Airing on the Fox Business Network, Monday, October 30, 2023, at 10:30 PM PT

Retrieved on: 
Friday, October 27, 2023
Ethos, Rat, American College, Social media, FRA, Pressure, Genetics, Elective surgery, Bureau, Interview, Third party, Disease, Silver, Hacking, Big Nuz, Record, Cannabinoid, BLM, IP, Mining, Pain, Sale, Veterinarian, Cat, ACVS, American College of Veterinary Surgeons, Injury, Internet, Osteoarthritis, Dog, Innovation system, Horse, 23andMe, FMW, BEC, Food, Coffee, Medical cannabis, Conference, Cosmetics, Bureau of Land Management, CSE, Quality of life, Animal, Privacy, Epilepsy, Communication, Email spoofing, FDA, Water, Patent, OTCQX, LG, Absorption, PROMO, Electricity, OTCQB, State Street Corporation, Television, Cryptocurrency, CBD, Street

Gold/Silver Mining – Lahontan Gold Corp.'s (OTCQB: LGCXF) (TSXV: LG) ($LGCXF) interview with Kimberly Ann, Founder, CEO, President, and Director.

Key Points: 
  • Gold/Silver Mining – Lahontan Gold Corp.'s (OTCQB: LGCXF) (TSXV: LG) ($LGCXF) interview with Kimberly Ann, Founder, CEO, President, and Director.
  • The study demonstrated the efficacy of Spryng as an excellent, non-invasive alternative in treating dogs with cranial cruciate disease and injuries.
  • Spryng is a naturally derived matrix of building proteins that mimics collagen tissue, significantly improving animals with cruciate damage and disease.
  • John believes as more published studies prove the viability of Spryng more veterinarians will adopt it as a front-line treatment.

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Retrieved on: 
Thursday, November 2, 2023
Cannabis, Science, MIT, Therapy, Intellectual property, Cannabinoid, University of Freiburg Faculty of Biology, Research, Technology Development Foundation of Turkey, Sleep, Laboratory, Partnership, Leukemia, Nobel Prize, Epilepsy, Patient, Massachusetts Institute of Technology, Pharmaceutical industry, Biology, Technion – Israel Institute of Technology

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new partnership with Cannasoul Analytics Ltd. ("Cannasoul") in support of research and development of pharmaceutical therapeutics. Cannasoul is founded by the Technion Research & Development Foundation ("TRDF"), the commercialization arm of The Technion – Israel Institute of Technology ("The Technion"), and world-renowned cannabis key opinion leader and researcher Professor Dedi Meiri from The Technion.

Key Points: 
  • Cannasoul is founded by the Technion Research & Development Foundation ("TRDF"), the commercialization arm of The Technion – Israel Institute of Technology ("The Technion"), and world-renowned cannabis key opinion leader and researcher Professor Dedi Meiri from The Technion.
  • Professor Meiri and The Technion founded Cannasoul in 2018 for the development of cannabinoid-based and other therapeutics for various indications and vertical markets.
  • Cannasoul has developed technology in large disease markets including leukemia ($12.7B by 20281), epilepsy ($14.7B by 20332), and sleep disorders ($73.5B by 20323).
  • "Cannasoul is pleased to welcome Synaptogenix as a key partner in our development of groundbreaking therapeutics derived from natural compounds.

Ovation Science Announces License Agreement for Its Topical / Transdermal Cannabis Products for Missouri

Retrieved on: 
Thursday, November 2, 2023
Cannabis, LAS, Food, Skin, Research, Distribution, CSE, Foot, Disease, Marketing, Uniloc USA, Inc. v. Microsoft Corp., THC, Cannabinoid, Agreement, Patient, Wellness, Criticism of the Food and Drug Administration, Drug, CBD, Ovation, Lists of United States Congress

VANCOUVER, BC and LAS VEGAS, Nov. 2, 2023 /PRNewswire/ - (CSE: OVAT) (OTCQB: OVATF) – Ovation Science USA Inc. ("Ovation" or the "Company"), with its proprietary topical and transdermal cannabis products powered by its patented skin delivery technology Invisicare®, today announced the signing of an exclusive licensing agreement for Ovation's topical / transdermal formulations for the state of Missouri.

Key Points: 
  • VANCOUVER, BC and LAS VEGAS, Nov. 2, 2023 /PRNewswire/ - (CSE: OVAT) (OTCQB: OVATF) – Ovation Science USA Inc. ("Ovation" or the "Company"), with its proprietary topical and transdermal cannabis products powered by its patented skin delivery technology Invisicare®, today announced the signing of an exclusive licensing agreement for Ovation's topical / transdermal formulations for the state of Missouri.
  • The Company's new licensee is MidWest Roots, LLC ("MidWest"); a company with a 65,000 square foot cannabis processing facility; one of the largest in Missouri.
  • "We are excited to partner with MidWest to bring our innovative topical cannabis products to the Missouri market, said Terry Howlett, President of Ovation.
  • In a recent in-house study, Ovation compared five CBD brand leaders to Ovation Science's topical CBD cream.